Follistatin 344 – Kodiac biolabs

Plain-language summaryIntrigue 75 / 100

Follistatin-344 is a 344-amino-acid form of follistatin, a protein that binds and inactivates myostatin (the muscle-growth brake). Used in research for muscle hypertrophy studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

Real myostatin biology but thin peptide-specific evidence and a troubled translational record limit the research case

Here’s the thing about follistatin 344: the underlying biology is genuinely compelling, and thats not nothing. Myostatin, the TGF-beta family member that McPherron and Lee identified in 1997, is one of the most robust negative regulators of skeletal muscle mass we know of. The follistatin/myostatin axis is multi-lab, multi-species validated, and the dramatic phenotype in myostatin-null mice, essentially double-muscled animals, is about as clear a genetic proof-of-concept as you get in muscle biology. The target is real. We’re not arguing otherwise.

What we’re debating is whether FST-344 as a research peptide is the right tool to study it. The 344 isoform is one of two major splice variants encoded by the FST gene; it carries a C-terminal extension with a heparin-binding domain that the 315 form lacks. This affects localization, circulating half-life, and probably how it sequesters activins and BMPs beyond myostatin. That isoform specificity isn’t trivial, and investigators working on tissue-specific follistatin signaling have real reasons to care which form they’re using. But the research peptide market’s FST-344 is not a properly characterized recombinant protein. Serious bench work on this axis typically draws from R&D Systems or Peprotech GMP-grade material with actual QC data behind it, not vendor peptides with unknown aggregation state and uncertain specific activity.

The translational story is complicated. Acceleron’s ACE-031, a soluble ActRIIB-Fc fusion that hits a related biological node by sequestering myostatin, activins, and other TGF-beta ligands, went into Phase 2 in Duchenne muscular dystrophy and was stopped for adverse events including nosebleeds and telangiectasias, with concerning vascular signals. The mechanism isn’t clean in humans: blocking the activin/BMP node broadly touches vascular biology, cardiac function, and bone homeostasis in ways still poorly understood. More recent myostatin-selective antibody programs like apitegromab are trying to thread this needle with better selectivity. Follistatin 344 doesnt offer that selectivity; it binds activin A and B alongside myostatin, which is probably where the vascular signal originates.

The most interesting human-relevant data in the broader field comes from gene therapy work. Jerry Mendell’s group at Nationwide Children’s Hospital has done AAV-delivered follistatin studies in Becker muscular dystrophy and inclusion body myositis, showing real increases in muscle volume on MRI. But thats follistatin as a gene therapy payload, not an injectable peptide, and those translational lessons dont map cleanly onto subcutaneous FST-344 administration. The target remains worth watching as myostatin-selective biologics advance in clinic. This specific form, as sold in the research peptide market without peptide-specific trial data, is not where a serious investigator puts time right now.

Novelty: 32
Mechanism promise: 48
In-category differentiation: 28
Evidence quality: 30
Translational signal: 28
Research bench value: 40

Rationale Myostatin antagonism via follistatin is well-validated multi-lab biology, but FST-344 as a vendor research peptide lacks peptide-specific evidence, the related ACE-031 program was stopped for adverse events, and better-characterized recombinant tools exist for investigators who actually need to work this axis.

Myostatin antagonist / follistatin isoform

An isoform of the endogenous myostatin antagonist follistatin, sold as a research peptide for muscle hypertrophy applications.

Abstract

Follistatin 344 is an isoform of the endogenous protein follistatin (the 344-residue form, encoded as one splice variant of the FST gene). Follistatin binds and antagonizes myostatin (GDF-8), a TGF-beta family member that negatively regulates skeletal muscle mass. Antagonizing myostatin produces increased muscle hypertrophy and reduced muscle atrophy in animal models. Follistatin 344 is sold as a research peptide for muscle development applications. The compound is administered subcutaneously or intramuscularly; oral bioavailability is poor. There is no human clinical trial record for follistatin 344 specifically; the related ACE-031 (a soluble activin receptor type IIB Fc fusion) was developed pharmaceutically and reached Phase 2. Investigational doses range widely with poorly characterized safety; chronic myostatin antagonism may have cardiac and tendon implications that are not adequately studied.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-089Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.